Procept BioRobotics CEO Larry Wood buys $498k in stock By Investing.com

Larry L. Wood, President and Chief Executive Officer of PROCEPT BioRobotics Corp (), recently increased his stake in the company. A Form 4 filing with the Securities and Exchange Commission revealed that Wood purchased common stock on August 7, 2026.

Wood acquired 23,900 shares of PROCEPT BioRobotics common stock. The shares were purchased at prices ranging from $20.67 to $21.02, with a weighted average price of $20.85 per share. The total value of these acquisitions amounted to $498,315. The shares are held indirectly through The Larry Wood Trust.The timing of Wood’s purchase coincides with notable stock momentum, as shares posted an 11% return over the past week. According to InvestingPro analysis, the stock appears undervalued at current levels. The company maintains a strong balance sheet with more cash than debt and liquid assets exceeding short-term obligations. For deeper insights into PRCT’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

The filing also noted that Wood’s holdings include 825 shares acquired on May 14, 2026, under the company’s 2021 Employee Stock Purchase Plan.

In other recent news, Procept BioRobotics reported a 19% increase in second-quarter revenue compared to the previous year, reaching $94.5 million and surpassing Wall Street expectations. Despite this revenue beat, the company experienced softer-than-expected procedure growth, prompting a revision of its full-year outlook for U.S. procedures. The earnings per share came in slightly below forecasts, with an adjusted loss of $0.47 compared to the expected loss of $0.46. Jefferies responded to these developments by lowering its price target for Procept BioRobotics from $25 to $20, while maintaining a Hold rating. Analyst Michael Sarcone highlighted that although second-quarter sales exceeded consensus estimates due to stronger system upgrades, U.S. procedures did not meet expectations. Meanwhile, William Blair downgraded the stock from Outperform to Market Perform, citing weaker-than-expected procedure volumes in the second quarter. The firm also adjusted its forward estimates, reducing 2027 procedure numbers by 9%. Procept BioRobotics reiterated its fiscal 2026 total sales guidance, projecting growth of 27% to 33%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.